The Claim
Apigenin partially inhibits DEHP-induced activation of the JNK signaling pathway in human endothelial cells, without affecting IκBα degradation or ERK1/2 phosphorylation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Apigenin reduces the activation of the JNK signaling pathway triggered by DEHP in human endothelial cells, but does not alter IκBα degradation or ERK1/2 phosphorylation.
See the scientific wording
Apigenin partially inhibits DEHP-induced activation of the JNK signaling pathway in human endothelial cells, but does not affect IκBα degradation or ERK1/2 phosphorylation, suggesting a specific mechanistic pathway for its anti-inflammatory effect.
When a toxic chemical called DEHP hits blood vessel cells, it turns on a signaling pathway called JNK, which tells the cells to make inflammatory signals. Apigenin stops this specific JNK signal from turning on, so the cells don’t produce those inflammatory signals. Other warning pathways in the cell stay untouched, so apigenin only targets this one problem.
What the research says
1 studyApigenin, a natural compound, blocks one specific warning signal (JNK) that gets turned on by a chemical called DEHP in blood vessel cells, but leaves two other signals alone — meaning it’s like a precise tool, not a broad sledgehammer.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.